Company intelligence / Profile preview
Etnova Therapeutics
Suwon-si, Gyeonggi-do, South Koreaetnova.co.kr ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Etnova Therapeutics is a South Korean biotech company developing small molecule drugs targeting cancer and cardiovascular diseases. Its lead candidate, ETN101—a multiple tyrosine kinase inhibitor—has entered Phase 1 clinical trials for advanced hepatocellular carcinoma. Preclinical assets target ischemic stroke and thrombosis. The company has demonstrated antitumor activity in animal models with its lead compound.
- Therapeutic areas
- OncologyCardiovascular
- Modalities
- Small moleculesMultiple tyrosine kinase inhibitors (mTKI)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Etnova Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Etnova Therapeutics.